CD19 and neoplasm: Flow cytometry analysis of 628 cases of relapsed or refractory (R/R) B-ALL from the Children’s Hospital of Philadelphia (CHOP) revealed that, before any treatment, about 17% of cases had more than 1% of CD19-negative tumor cells.